nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.02.2013 | short review

Management of immunosuppression in the treatment of chronic lymphocytic leukemia

verfasst von: Jutta Auberger, MD, Prof. Richard Greil, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

In patients with chronic lymphocytic leukemia (CLL), infections exert a substantial influence on morbidity and mortality. Hypogammaglobulinemia is one important predisposing factor for development of infections. The use of purine analogs, such as fludarabine, and monoclonal antibodies, such as rituximab and alemtuzumab, has introduced a new spectrum of infectious complications caused by pathogens such as Pneumocystis jiroveci, mycobacteria, listeria, and herpes viruses, as well as of fungal infections; these infections are mainly related to cellular immunosuppression induced by these agents. This short review focusses on risk factors, the causative spectrum of infectious complications, and possible preventive approaches in CLL patients, including antimicrobial, immunoglobulin prophylaxis, and vaccination strategies.

Vorheriger Artikel Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications

Nächster Artikel Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic

Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009;6(7):405–18.PubMedCrossRef

Asslaber D, Grossinger EM, Girbl T, Hofbauer SW, Egle A, Weiss L, Greil R, Hartmann TN. Mimicking the microenvironment in chronic lymphocytic leukaemia—where does the journey go? Br J Haematol. 2013;160:711–4.

Bennardo S, Iacovelli S, Gobessi S, Suljagic M, Bilbao D, Eckl-Dorna J, Wang H, Cornall RJ, Clarke SH, Croce CM, Efremov DM. The nature of the antigen determines leukemia development and behavior in the Eµ-TCL1 transgenic mouse model of CLL. Abstract Book, 54th ASH Annual Meeting, 2012.

Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145–53.PubMedCrossRef

Sinisalo M, Aittoniemi J, Koski T, Tobin G, Thunberg U, Sundstrom C, Rosenquist R, Kayhty H, Vilpo J. Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status. Leuk Lymphoma. 2004;45(12):2451–4.PubMedCrossRef

Morrison VA, Hibbs JR, Janoff EN. Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma. Blood. 1996;88(Suppl. 1):240a.

Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev. 2006;32(5):377–89.PubMedCrossRef

Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793–8.PubMedCrossRef

Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, Piantadosi S, Seifter E, Ambinder RF, Vogelsang G, Grever MR. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96(1):71–5.PubMed

10.

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.PubMedCrossRef

11.

Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S, Schweighofer C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885–91.PubMedCrossRef

12.

Smith TF, Espy MJ, Mandrekar J, Jones MF, Cockerill FR, Patel R. Quantitative real-time polymerase chain reaction for evaluating dnaemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis. 2007;45(8):1056–61.PubMedCrossRef

13.

Sandherr M, Einsele H, Hebart H, Kahl C, Kern W, Kiehl M, Massenkeil G, Penack O, Schiel X, Schuettrumpf S, Ullmann AJ, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol. 2006;17(7):1051–9.PubMedCrossRef

14.

Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol. 2009;88(2):121–32.PubMedCrossRef

15.

Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, Tarnani M, Fadda G, Sica S, Leone G. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica. 2004;89(10):1248–52.PubMed

16.

Slager SL, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti LZ, Leis JF, Camp NJ, et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2011;117(6):1911–6.PubMedCrossRef

17.

Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis b virus reactivation in the biologic therapy era. World J Gastroenterol. 2011;17(34):3881–7.PubMedCrossRef

18.

O’Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma. 2006;7(2):125–30.PubMedCrossRef

19.

Sinisalo M, Aittoniemi J, Kayhty H, Vilpo J. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44(4):649–52.PubMedCrossRef

20.

Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001;19(13–14):1671–7.PubMedCrossRef

21.

Leukemia CGftSoIiCL. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med. 1988;319:902–7.CrossRef

22.

Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, Levato D, Nobile F, Carotenuto M, Liso V, Rotoli B. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica. 1996;81(2):121–6.PubMed

Titel: Management of immunosuppression in the treatment of chronic lymphocytic leukemia
verfasst von: Jutta Auberger, MD
Prof. Richard Greil, MD
Publikationsdatum: 01.02.2013
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-013-0072-1

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications

Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic

Maintenance therapy in NSCLC

Breast cancer treatment in Hungary—first step into molecular medicine

Video-assisted thoracoscopic pneumonectomy: a minimally invasive approach for a rare inidication

The role of maintenance strategies in upper gastrointestinal (GI) and pancreatic carcinoma